LASN01

DRUG3 trials

Sponsors

Lassen Therapeutics 1 Inc., Lassen Therapeutics 1 PTY LTD, Lassen Therapeutics Inc.

Conditions

Endocrine System DiseasesEye DiseasesGraves OphthalmopathyGraves OrbitopathyOrbital DiseasesProptosisPulmonary FibrosisThyroid Associated Ophthalmopathy

Phase 1

A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

CompletedNCT05331300

Lassen Therapeutics 1 PTY LTDPulmonary Fibrosis, Thyroid Eye Disease

Start: 2022-06-06End: 2024-11-27Updated: 2024-12-30

Phase 2

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

CompletedNCT06226545

Lassen Therapeutics Inc.Endocrine System Diseases, Eye Diseases, Graves Ophthalmopathy +5

Start: 2024-03-05End: 2025-04-22Updated: 2026-03-09

A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients with Thyroid Eye Disease

CompletedCTIS2023-508161-32-00

Lassen Therapeutics 1 Inc.Thyroid Eye Disease

Start: 2024-03-28End: 2025-04-02Target: 11Updated: 2025-04-11